PAVmed Names Shaun O’Neil Chief Commercial Officer
July 11 2018 - 7:30AM
Business Wire
Medical device veteran joins as company
approaches important regulatory and commercial milestones
Immediate focus on building commercialization
platforms for CarpX and EsoCheck
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or
“PAVmed”), a highly differentiated, multiproduct medical device
company, today announced that it has named Shaun M. O’Neil to serve
as its first Chief Commercial Officer. Mr. O’Neil will oversee all
aspects of the domestic and international commercialization of
PAVmed’s products including sales and marketing, clinician
engagement and professional education. He will officially assume
his role on July 23 reporting directly to Lishan Aklog, M.D.,
PAVmed’s Chairman and Chief Executive Officer.
“I am incredibly excited to welcome Shaun O’Neil to the PAVmed
team,” said Dr Aklog. “As PAVmed approaches important regulatory
and commercial milestones, the time has come to begin laying the
foundation for our transition from a development-stage to a
commercial-stage company. I am confident Shaun is the best person
to lead this effort.
“Dr. Brian deGuzman, PAVmed’s Chief Medical Officer, Michael
Glennon, our Vice Chairman, and I have been direct witnesses to
Shaun’s industry savvy, leadership skills, vision, work ethic,
professionalism and integrity since AngioDynamics first joined us
in discussions that led to its acquisition of our first company,
Vortex Medical, and its groundbreaking, life-saving AngioVac®
device,” Dr Aklog continued. “AngioVac is a challenging device to
commercialize, with multiple specialty call points and the need for
intense clinical support. Shaun played a critical role in
establishing a vision and plan for AngioVac’s commercialization and
successfully executed on that plan with his team. We observed that
he is equally as comfortable in the board room crafting strategy as
he is in the trenches with his sales reps calling on physicians and
hospitals to adopt a new, groundbreaking technology for the benefit
of their patients. That professional versatility, drive to excel
and commitment to patients aligns perfectly with our business model
and company ethos.”
“I have watched with keen interest as this unique and disruptive
company has made remarkable progress since its founding by a team
that I learned to respect and admire over several years of working
closely on the commercialization of AngioVac,” said Mr. O’Neil. “I
am very excited to join PAVmed as it approaches the expected
commercial launch of two highly innovative products with
billion-dollar market opportunities. I enthusiastically accepted
Dr. Aklog’s offer to join this highly accomplished team because I
have been a true believer in its vision and business model since
its inception, and because I believe the Company’s lead products
have all the hallmarks of commercial blockbusters that will benefit
many patients worldwide while creating significant value for
PAVmed’s shareholders.
“I have spent a substantial part of my career providing
physicians and their patients with less invasive and more
cost-effective solutions for unmet clinical needs,” Mr. O’Neil
added. “In CarpX and EsoCheck, I see two products with great
potential to transform the care of patients with highly prevalent
and debilitating or life-threatening conditions. PAVmed has the
cash runway and streamlined business model that I believe will
allow us to build tailored commercialization platforms for each
product that will be ready to activate upon regulatory
clearance.”
Mr. O’Neil brings to PAVmed more than 15 years of sales and
marketing leadership, and product and business development
expertise in both startup and established companies, including a
particularly strong track record in growing sales and increasing
market share for innovative medical devices. Since 2011, Mr. O’Neil
has held various sales and marketing leadership positions with
AngioDynamics (Nasdaq: ANGO), a leading provider of innovative
medical devices used by interventional radiologists, interventional
cardiologists, surgeons, and other physicians for the
minimally-invasive diagnosis and treatment of cancer and peripheral
vascular disease. Most recently he served as regional sales manager
for its peripheral vascular division, where he oversaw multiple
territory managers and clinical specialists. He was responsible for
multiple product launches and was a perennial recipient of sales
and performance awards. Prior to AngioDynamics, he served in
various sales, marketing and engineering roles at Aycan Medical
Systems, a privately-held medical imaging company.
Mr. O’Neil received a B.S. in management information systems
from Alfred University and an M.B.A. from the Rochester Institute
of Technology.
About PAVmed
PAVmed Inc. is a highly differentiated, multiproduct medical
device company employing a unique business model designed to
advance innovative products to commercialization much more rapidly
and with significantly less capital than the typical medical device
company. This proprietary model enables PAVmed to pursue an
expanding pipeline strategy with a view to enhancing and
accelerating value creation. PAVmed’s diversified pipeline of
products address unmet clinical needs encompassing a broad spectrum
of clinical areas with attractive regulatory pathways and market
opportunities. Its three lead products provide groundbreaking
approaches to carpal tunnel syndrome (CarpX™), precancerous
conditions of the esophagus (EsoCheck), vascular access (PortIO™)
and pediatric ear infections (DisappEAR™). The company is also
developing innovative products in other areas, such as medical
infusions and tissue ablation, while seeking to further expand its
pipeline through engagements with clinician innovators and leading
academic medical centers. For further information, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, based upon the current beliefs and expectations of
PAVmed’s management, are subject to risks and uncertainties, which
could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences
include, among other things; volatility in the price of PAVmed’s
common stock, Series W Warrants and Series Z Warrants; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required
advance PAVmed’s products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from PAVmed’s preclinical studies; whether and when
PAVmed’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s products once cleared and commercialized;
our ability to raise additional funding and other competitive
developments. PAVmed has not yet received clearance from the FDA or
other regulatory body to market any of its products. New risks and
uncertainties may arise from time to time and are difficult to
predict. All of these factors are difficult or impossible to
predict accurately and many of them are beyond PAVmed’s control.
For a further list and description of these and other important
risks and uncertainties that may affect PAVmed’s future operations,
see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk
Factors” in any Quarterly Reports on Form 10-Q filed by PAVmed
after its most recent Annual Report. PAVmed disclaims any intention
or obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180711005147/en/
InvestorsLHA Investor RelationsKim
Sutton Golodetz, 212-838-3777kgolodetz@lhai.comorMediaPAVmed Inc.212-949-4319info@pavmed.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Apr 2023 to Apr 2024